ADA 2021 Highlights

(Opcional)
Privacy Policy.



Available on the Medfyle App

Welcome to ADA 2021 Highlights

The 2021 ADA Virtual Scientific Sessions offered researchers and health care professionals the unique opportunity to share ideas and learn about the significant advances and breakthroughs in diabetes. With more than 180 sessions and 1,000 original research presentations, the Scientific Sessions, held June 25–29, offered a comprehensive educational programming covering the latest in the field of diabetes. We are pleased to present these ADA Highlights selections.

Today@ADA

Welcome to Today@ADA – a round-up of our picks from the day’s program at the 81st Scientific Sessions of the American Diabetes Association. Each day Dana Dabelea, Chair of the ADA's 81st Scientific Sessions' Planning Commettee, interviewed one of ADA's 81st Scientific Sessions' key speakers, and presentated her three top picks from everything that went live – with personal takes and commentary.
You can revisit anything you missed and want to catch-up with in full in the on-demand sessions.

ADA Leadership Interviews

 
 
36
What are your objectives for your term as President of Health Care & Education at the ADA?
196
What will be the long-term professional impact of COVID-19 on clinical care for people with diabetes?
481
How did the pandemic brought an epidemic to light?
716
What are some of the more common mental health issues faced by children with diabetes” or children with insulin-treated diabetes?
 
 
32
How has the overall ADA strategy changed as a result of the pandemic? What does the future hold?
150
The COVID-19 pandemic has disrupted life as we knew it, but it has also offered opportunities – what would you say has changed for the better in diabetes as a result of the pandemic?
216
ADA, together with the EASD, is working on a new consensus report on the management of type 1 diabetes in adults: What’s new?
488
You are only the fifth women to hold the position of ADA President, Science & Medicine - for many years, research and clinical trials involved only men, how important is it for young female diabetologists to be part of the future of research in diabetes?

ADA Faculty Interviews

 
 
18
What percentage of people with type 2 diabetes have cardiorenal complications?
60
What are the key metabolic risks?
120
What role do SGLT2 inhibitors and GLP-1 receptor agonists have to play?
202
How many people who need these agents receive them?
263
What needs to change to fully mitigate cardiorenal risks?
 
 
17
Is there a perception that diabetes care is not the responsibility of cardiologists?
93
What is the link between diabetes and cardiovascular outcomes?
185
What have we learnt from the cardiovascular outcomes trials with SGLT2 inhibitors and GLP-1 receptor agonists?
717
What role could these agents play in the inpatient cardiovascular care setting?
 
 
19
What did you hope to show with the TrialNet study?
71
Have there been any surprises in the results?
203
How can this information shape future treatment options for type 1 diabetes?
See More

Expert Overviews

 
 
 
 
 
See More

Summaries

See More

Posters

See More
About ADA Feedback Post Test